| |
EIB (n = 21)
|
TB-AOI (n = 20)
|
|---|
|
Phone Follow-up – no. (%)
|
n = 13 (62)
|
n = 11 (55)
|
|
Time post ATT – month (year)
|
|
Median
|
61 (5.1)
|
49 (4.1)
|
|
IQR
|
34 (2.8)
|
48 (4)
|
|
Responses
|
|
“Do you still have (EIB/TB-AOI)?”
|
|
Resolved – no. (%)
|
8 (62)
|
2 (18)
|
|
Better
|
2 (15)
|
3 (28)
|
|
Worse
|
0 (0)
|
0 (0)
|
|
No change
|
3 (23)
|
6 (54)
|
|
“How did your condition respond to the ATT?”
|
|
Min (< 25% improvement)
|
1 (8)
|
8 (73)
|
|
Mod (~ 50%)
|
1 (8)
|
1 (9)
|
|
Significantly (~ 75%)
|
2 (15)
|
0 (0)
|
|
Complete (100%)
|
7 (54)
|
2 (18)
|
|
“How did you tolerate the ATT?”
|
|
Poorly
|
5 (38)
|
3 (28)
|
|
Well
|
5 (38)
|
2 (18)
|
|
No issue
|
3 (24)
|
6 (54)
|
- EI – erythema induratum, TB-AOI – tuberculosis-associated ocular inflammation, ATT – anti-tubercular therapy
